Evidence map›Paper›PMID 39324008›Full record

ArticleFrontiers in oncology2024

Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma.

Rajan Singh, Anand K Thotakura, Suresh Alati, Alla Lisok, Zirui Jiang, Vanessa F Merino, Il Minn, Santosh Yadav, Mark C Markowski, Yasser Ged and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Rajan SinghRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, United States.
Anand K ThotakuraRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, United States.
Suresh AlatiRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, United States.
Alla LisokRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, United States.
Zirui JiangRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, United States.
Vanessa F MerinoRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, United States.
Il MinnRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, United States.
Santosh YadavRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, United States.
Mark C MarkowskiDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States.
Yasser GedDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States.
Christian P PavlovichDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States.
Nirmish SinglaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States.
Lilja B SolnesRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, United States.
Michael A GorinThe Milton and Carroll Petrie Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Martin G PomperDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States.
Steven P RoweDepartment of Radiology, University of North Carolina, Chapel Hill, NC, United States.
Sangeeta Ray BanerjeeRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, United States.

Funding

Training/Dissemination-Resource for Molecular Imaging Agents in Precision MedicineP41EB024495 · NIBIB · UT SOUTHWESTERN MEDICAL CENTER · PI MARTIN G POMPER · 2017 to 2026
$11.8M
Targeted inhibition of metabolic pathways to enhance radiopharmaceutical therapyR21CA267374 · NCI · JOHNS HOPKINS UNIVERSITY · PI RAY, SANGEETA · 2022 to 2023
$416k
NCI NIH HHS R21 CA267374NIBIB NIH HHS P41 EB024495
6 · The paper itself

Abstract

Introduction: Renal cell carcinoma (RCC) represents cancer originating from the renal epithelium and accounts for > 90% of cancers in the kidney. Prostate-specific membrane antigen (PSMA) is overexpressed in tumor-associated neovascular endothelial cells of many solid tumors, including metastatic RCC. Although studied in several small clinical studies, PSMA-based imaging and therapy have not been pursued rigorously in preclinical RCC. This study aimed to evaluate the preclinical performance of PSMA-based radiotheranostic agents in a relevant murine model. Methods: A PSMA-overexpressing murine cell line, PSMA+ RENCA, was developed by lentiviral transduction. PSMA-based theranostic agents, Results: Cellular uptake of Conclusion: The results suggest that a theranostic strategy targeting PSMA, employing PET and α-emitting radiopharmaceuticals, enabled tumor growth control and enhanced survival in a relevant immunocompetent murine model of RCC. These studies provide the rationale for clinical studies of PSMA-targeted theranostic agents in patients with RCC.

Indexed as

actinium-225alpha-particle emitting radionuclidegallium-68lutetium-177positron-emission tomographyprostate-specific membrane antigentargeted radiopharmaceutical therapyβ-particle emitting radionuclide

Identifiers

PMID39324008
PMCPMC11423292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.